Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States, shoring up domestic manufacturing as President Donald Trump threatens new tariffs on pharmaceuticals.

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than the last—the company’s spree has begged the question: What will they do | At a press conference in Washington,

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas,

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.

The push to onshore manufacturing was already underway at Lilly, which has been investing heavily to boost production capacity for Zepbound and Mounjaro.